Evidence map›Paper›PMID 38366087›Full record

ArticleLeukemia2024

The UBE2J2/UBE2K-MARCH5 ubiquitination machinery regulates apoptosis in response to venetoclax in acute myeloid leukemia.

Shan Lin, Constanze Schneider, Angela H Su, Gabriela Alexe, David E Root, Kimberly Stegmaier

Abstract read
In one paragraph

Article in Leukemia, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Shan Lin *Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Constanze Schneider *Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Angela H SuDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Gabriela AlexeDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-5668-6297
David E RootBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Kimberly StegmaierDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Kimberly_stegmaier@dfci.harvard.edu.ORCID http://orcid.org/0000-0003-0218-7895

Funding

Targeting SYK Kinase in AMLP50CA206963 · NCI · DANA-FARBER CANCER INST · PI STEGMAIER, KIMBERLY · 2017 to 2021
$10.6M
Integrating Transforming Approaches to Identify and Target New Vulnerabilities in CancerR35CA210030 · NCI · DANA-FARBER CANCER INST · PI STEGMAIER, KIMBERLY · 2016 to 2022
$7.3M
Targeting Pediatric Cancer VulnerabilitiesR35CA283977 · NCI · DANA-FARBER CANCER INST · PI Kimberly Stegmaier · 2023 to 2026
$4.2M
Characterizing the role of MARCH5 in apoptosis regulation in acute myeloid leukemiaR00CA263161 · NCI · SEATTLE CHILDREN'S HOSPITAL · PI Shan Lin · 2024 to 2026
$747k
Characterizing the role of MARCH5 in apoptosis regulation in acute myeloid leukemiaK99CA263161 · NCI · DANA-FARBER CANCER INST · PI LIN, SHAN · 2021 to 2022
$272k
NCI NIH HHS K99 CA263161NCI NIH HHS P50 CA206963NCI NIH HHS R00 CA263161NCI NIH HHS R35 CA210030NCI NIH HHS R35 CA283977
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Leukemia, Myeloid, AcuteSulfonamidesApoptosisBridged Bicyclo Compounds, HeterocyclicHumansProto-Oncogene Proteins c-bcl-2UbiquitinationUbiquitin-Conjugating EnzymesBridged Bicyclo Compounds, HeterocyclicProto-Oncogene Proteins c-bcl-2SulfonamidesUBE2J2 protein, humanUBE2K protein, humanUbiquitin-Conjugating Enzymesvenetoclax

Identifiers

PMID38366087
PMCPMC10912020

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.